Decreased Macrophage Paraoxonase 2 Expression in Patients With Hypercholesterolemia Is the Result of Their Increased Cellular Cholesterol Content: Effect of Atorvastatin Therapy
Authors:
- 1 January 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (1) , 175-180
Abstract
Objective— To analyze paraoxonase2 (PON2) expression in human monocyte-derived macrophages (HMDM) from patients with hypercholesterolemia in relation to cellular cholesterol and oxidative stress. Methods and Results— Ten healthy subjects (controls) and 10 patients with hypercholesterolema who received 20-mg/d atorvastatin participated in the study. The patients’ versus controls’ HMDM demonstrated increased cholesterol content (270%) and oxidative stress (30% to 45%). Atorvastatin therapy reduced these parameters (59% and 25%, respectively). The patients’ versus controls’ macrophage-PON2 mRNA expression and PON2 activity were lower (100% and 40%, respectively), and atorvastatin therapy increased these parameters (76% and 200%, respectively). Untreated patient HMDM incubation with atorvastatin (0 to 10 μmol/L) resulted in a dose-dependent reduction in cellular cholesterol content and in cell-mediated low-density lipoprotein (LDL) oxidation up to 79% and 66%, respectively. In parallel, PON2 mRNA expression and PON2 activity increased dose-dependently up to 3.6- and 2.1-fold, respectively. On incubation of control HMDM with acetylated-LDL or aggregated-LDL, cellular cholesterol content increased (77% and 100%), and macrophage-PON2 activity decreased (49% and 22%), respectively. In contrast, oxidized LDL increased both cellular oxidative stress and PON2 expression. Conclusions— HMDM-PON2 expression is reduced in patients with hypercholesterolemia as a result of their increased cellular cholesterol content. Atorvastatin therapy reduced both macrophage oxidative stress and cholesterol content, and upregulated PON2 expression, thus contributing to attenuation of foam cells formation.Keywords
This publication has 29 references indexed in Scilit:
- Simvastatin Modulates Expression of the PON1 Gene and Increases Serum ParaoxonaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout miceFree Radical Biology and Medicine, 2003
- Statin use in acute coronary syndromes: cellular mechanisms and clinical evidenceCurrent Opinion in Lipidology, 2002
- Inflammation in atherosclerosisNature, 2002
- Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density LipoproteinJournal of Biological Chemistry, 2001
- Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against OxidationJournal of Biological Chemistry, 2000
- Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and AtherosclerosisJournal of Biological Chemistry, 2000
- Oxidized Monocyte-Derived Macrophages in Aortic Atherosclerotic Lesion from Apolipoprotein E-Deficient Mice and from Human Carotid Artery Contain Lipid Peroxides and OxysterolsBiochemical and Biophysical Research Communications, 2000
- Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.Journal of Clinical Investigation, 1998
- Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993